ArticleContemporary clinical trials communications2023

A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9-12 month old healthy infants.

Subhash Thuluva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.